In addition, the EA group was characterized by a higher incidence of allergy history and omalizumab usage, increased Fractional exhaled nitric oxide (FeNO) level, and specific and total IgE, but lower Asthma control test (ACT) scores than those in other groups (Table 1). Here, IGHE is linked to allergic disease.